Pasithea Therapeutics confirms its Board of Directors has previously formed a special committee of independent and disinterested directors to assess an unsolicited proposal from Lucy Scientific Discovery to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock. Consistent with its fiduciary obligations to all shareholders, the Special Committee continues to actively evaluate the Lucy proposal, in consultation with its independent financial advisor, H.C. Wainwright & Co., and its legal advisors, Lowenstein Sandler LLP and Richards Layton & Finger, P.A. The Special Committee is comprised of independent directors Simon Dumesnil and Alfred Novak.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KTTA:
- Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
- Lucy Scientific Discovery reiterates proposal to acquire Pasithea Therapeutics
- Pasithea Therapeutics completes GMP manufacturing for PAS-004
- Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
- Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.